-
Product Insights
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) - Drugs In Development, 2024
Empower your strategies with our Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) – Drugs In Development, 2024 report and make more profitable business decisions. Interstitial lung disease (ILD) is a term that covers a variety of disorders that cause scarring or inflammation of the lung tissue. The scarring or inflammation affects the ability of the lungs to transfer oxygen to the blood. ILD can be caused by many factors, such as exposure to environmental toxins, certain medications, autoimmune diseases, infections, or...
-
Product Insights
Ventilator Associated Pneumonia (VAP) - Drugs In Development, 2024
Empower your strategies with our Ventilator Associated Pneumonia (VAP) – Drugs In Development, 2024 report and make more profitable business decisions. Ventilator-associated pneumonia (VAP) is pneumonia that develops 48 hours or longer after mechanical ventilation is given by means of an endotracheal tube or tracheostomy. Ventilator-associated pneumonia (VAP) results from the invasion of the lower respiratory tract and lung parenchyma by microorganisms. The most important signs are fever, low body temperature, new purulent sputum, and hypoxemia (decreasing amounts of oxygen in...
-
Product Insights
Bronchiectasis - Drugs In Development, 2024
Empower your strategies with our Bronchiectasis – Drugs In Development, 2024 report and make more profitable business decisions. Bronchiectasis is a chronic condition where the walls of the bronchial tubes are permanently damaged. This damage allows bacteria and mucus to build up in the lungs. Bronchiectasis is divided into two categories: cystic fibrosis (CF) bronchiectasis and non-CF bronchiectasis. Symptoms include chronic coughing, shortness of breath, chest pain, fatigue, weight loss, and fever. Causes of bronchiectasis include inhaling a foreign object, cystic...
-
Product Insights
Bronchitis - Drugs In Development, 2024
Empower your strategies with our Bronchitis – Drugs In Development, 2024 report and make more profitable business decisions. Bronchitis is an inflammation of the lining of bronchial tubes, which carry air to and from lungs. Symptoms include cough that produces mucus (sputum), which may be blood streaked; shortness of breath aggravated by exertion or mild activity; frequent respiratory infections worsen symptoms; wheezing, fatigue, and headaches. Risk factors include smoking, older age and gastric reflux. The Bronchitis drugs in development market research...
-
Product Insights
Sleep Apnea - Drugs In Development, 2024
Empower your strategies with our Sleep Apnea – Drugs In Development, 2024 report and make more profitable business decisions. Sleep apnea, a prevalent condition, involves the recurrent interruption and resumption of breathing during sleep. Two main types exist, obstructive and central sleep apnea. Obstructive sleep apnea occurs when the upper airway is frequently blocked, diminishing or halting airflow. Common risk factors include obesity, enlarged tonsils, and hormonal changes. Central sleep apnea results from the brain's failure to send necessary signals for...
-
Product Insights
Chronic Cough - Drugs In Development, 2024
Empower your strategies with our Chronic Cough – Drugs In Development, 2024 report and make more profitable business decisions. Chronic cough is a respiratory disorder, characterized by a persistent cough lasting at least eight weeks or longer. Coughing is a natural defense mechanism, clearing bronchial secretions and eliminating inhaled foreign particles. Chronic cough can result from various causes, including respiratory infections like bronchitis or pneumonia, gastroesophageal reflux disease (GERD), asthma, and postnasal drip. Understanding and addressing the underlying condition is essential...
-
Product Insights
Community Acquired Pneumonia - Drugs In Development, 2024
Empower your strategies with our Community Acquired Pneumonia – Drugs In Development, 2024 report and make more profitable business decisions. Community-acquired pneumonia (CAP) is defined as pneumonia acquired outside a hospital or long-term care facility. Symptoms include cough, fever, shaking chills, confusion, headache, and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis, and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle. The Community Acquired Pneumonia drugs in development market research...
-
Product Insights
Bronchopulmonary Dysplasia - Drugs In Development, 2024
Empower your strategies with our Bronchopulmonary Dysplasia – Drugs In Development, 2024 report and make more profitable business decisions. Bronchopulmonary dysplasia (BPD) is a form of chronic lung disease that develops in preterm neonates treated with oxygen and positive-pressure ventilation. Symptoms of BPD include tachypnea, tachycardia, increased respiratory effort (with retractions, nasal flaring, and grunting), and bluish skin color. Risk factors include congenital heart disease and severe respiratory or lung infection; premature babies who have a low birth weight seem to...
-
Product Insights
Obstructive Sleep Apnea - Drugs In Development, 2024
Empower your strategies with our Obstructive Sleep Apnea – Drugs In Development, 2024 report and make more profitable business decisions. Obstructive sleep apnea (OSA) is defined by episodes of either complete collapse or partial collapse of the airway during sleep, accompanied by a reduction in oxygen saturation or awakening from sleep. This disruption leads to fragmented and nonrestorative sleep. The implications of OSA extend to various aspects of health, including cardiovascular well-being, mental health, overall quality of life, and safety while...
-
Product Insights
Seasonal Allergic Rhinitis - Drugs In Development, 2024
Empower your strategies with our Seasonal Allergic Rhinitis – Drugs In Development, 2024 report and make more profitable business decisions. Seasonal allergic rhinitis (SAR), commonly referred to as hay fever, is an inflammatory condition affecting the upper airways in response to exposure to airborne allergens, typically pollen from trees, grasses, and weeds, particularly prevalent in certain seasons. This condition manifests in sensitized individuals, giving rise to symptoms such as sneezing, nasal congestion, a runny nose, itchy or watery eyes, and fatigue....
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.